We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tripos Announces Partnerships with Pharmaceutical and Life Science Companies
News

Tripos Announces Partnerships with Pharmaceutical and Life Science Companies

Tripos Announces Partnerships with Pharmaceutical and Life Science Companies
News

Tripos Announces Partnerships with Pharmaceutical and Life Science Companies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tripos Announces Partnerships with Pharmaceutical and Life Science Companies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tripos, Inc. has announced collaborations with several prominent pharmaceutical and life science organizations across Europe and North America to provide knowledge-driven customized chemistry services.

These agreements encompass a combination of partnerships and extensions with CeNeS Ltd., Gemin X Biotechnologies Inc., Genzyme Corp., GlaxoSmithKline Research and Development Ltd., and Schering-Plough Research Institute.

Drawing upon Tripos' proprietary knowledge-driven chemistry process, the partnerships encompass a range of research activities including medicinal chemistry programs, the development of LeadQuest® compounds, follow-up libraries based on hits from LeadQuest, provision of synthetic protocols, fragment-based screening and LeadHopping® projects.

"Tripos is delighted to be working with these pioneering pharmaceutical and life science companies," said Dr. John P. McAlister, president and CEO of Tripos.

"Their decision to select Tripos Discovery Research as their drug discovery partner underscores the quality of our work, the innovation we bring to our partners and our solid reputation for success in this field."

"As we enter 2006, we are committed to expanding our service and client base to provide more integrated drug discovery services."

"We are now engaged in more discovery research programs than ever before, and we look forward to generating value on behalf of our clients."

Advertisement